within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EA03_Apraclonidine;

model Apraclonidine
  extends Pharmacolibrary.Drugs.ATC.S.S01EA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EA03</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Apraclonidine is an alpha-2 adrenergic agonist primarily used in ophthalmology to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is commonly administered topically as eye drops. Apraclonidine is approved for short-term control of elevated IOP, such as after laser eye surgery, due to tachyphylaxis and side effects with longer-term use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals after topical ophthalmic administration. No detailed clinical population PK studies or compartmental model publications are available; all parameter values are estimated based on general knowledge of adrenergic agonists and limited data from product labels.</p><h4>References</h4><ol><li><p>Gharagozloo, NZ, et al., &amp; Brubaker, RF (1988). Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). <i>Ophthalmology</i> 95(9) 1217–1220. DOI:<a href=&quot;https://doi.org/10.1016/s0161-6420(88)33038-1&quot;>10.1016/s0161-6420(88)33038-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3062536/&quot;>https://pubmed.ncbi.nlm.nih.gov/3062536</a></p></li><li><p>Watanabe, K, et al., &amp; Nagaki, Y (2001). Effects of alpha(2)-adrenergic agonists on lipopolysaccharide-induced aqueous flare elevation in pigmented rabbits. <i>Japanese journal of ophthalmology</i> 45(3) 221–226. DOI:<a href=&quot;https://doi.org/10.1016/s0021-5155(00)00386-5&quot;>10.1016/s0021-5155(00)00386-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11369369/&quot;>https://pubmed.ncbi.nlm.nih.gov/11369369</a></p></li><li><p>McCannel, C, et al., &amp; Brubaker, RF (1991). Topical flurbiprofen pretreatment does not block apraclonidine&#x27;s effect on aqueous flow in humans. <i>Archives of ophthalmology (Chicago, Ill. : 1960)</i> 109(6) 810–811. DOI:<a href=&quot;https://doi.org/10.1001/archopht.1991.01080060074028&quot;>10.1001/archopht.1991.01080060074028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1675050/&quot;>https://pubmed.ncbi.nlm.nih.gov/1675050</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Apraclonidine;
